Notable Labs, IntelliCyt Announce Collaboration
News Jun 24, 2016
IntelliCyt has announced a collaboration with Notable Labs to further the development of a predictive personalized medicine platform. Notable Labs helps oncologists identify effective therapies that they can prescribe by testing them on a patient’s own cells. This approach promises tailored treatment options fast enough for doctors to put to use. By testing a broad set of drugs and drug combinations, Notable Labs is able to functionally profile cancer cells, which leads to a better understanding of the biological mechanisms of the patient’s cancer.
Providing this information to physicians can improve treatment outcomes while reducing side effects. Notable Labs will utilize IntelliCyt’s iQue® Screener PLUS platform in a fully automated, high-throughput laboratory to immune-profile phenotypic and functional endpoints of cells and secreted proteins through cell- and bead-based assays. Prioritized treatment options will be highlighted in reports to clinicians using Notable Lab’s screening process with IntelliCyt’s immune-profiling technology.
The IntelliCyt iQue Screener platform, an integrated instrument, software and reagent system, offers a proprietary high-throughput sampling capability that enables the rapid assessment of cells and beads in suspension in 96-, 384-, and 1536-well plates. In addition to the fastest plate processing speed in the industry for this type of analysis, miniaturization of the assay is possible to save reagent cost and conserve precious samples.
Additionally, high content, multiplex readouts are generated on each individual cell or bead via the flow cytometry-based detection system. Data analysis and visualization using ForeCyt® software, provides unique insights into the complex biology of disease. “IntelliCyt is expanding into the personalized medicine field by leveraging our high throughput, immune-profiling capabilities,” said Janette Phi, Chief Business Officer of IntelliCyt. “We are excited to collaborate with Notable Labs in this transformational path of enabling potentially life-saving therapies.”
“The iQue Screener PLUS offers deeper insights into which treatments target cancer cells while sparing a patient’s healthy cells”, said Matt De Silva, CEO of Notable Labs. “High-throughput flow cytometry provides us with new capabilities to observe real-time drug sensitivity for individual patients on a single cell level.”
Insulin Goes Viral: Diabetes and Cancer-causing Mechanisms ExploredNews
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018